Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022
Data featured at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition from December 10-13, 2022, reinforce Sanofi’s commitment to transforming care for people living with multiple myeloma (MM) and other difficult-to-treat blood cancers.
Peter C. Adamson, MD
Global Head of Oncology Development
“Data to be presented at this year’s ASH Meeting demonstrate our commitment to improving the outcome for patients with cancer. This includes presentations for Sarclisa, an anti-CD38 antibody of choice for patients with multiple myeloma and a cornerstone of our strategy to broaden our portfolio in hematologic malignancies. We are proud to be advancing knowledge and the treatment of patients with multiple myeloma, by sharing emerging data from our research efforts.”
The first Sarclisa oral presentation will detail results from a subgroup analysis of the Phase 3 IKEMA trial, which in May 2022 reported updated median progression-free survival results in combination with carfilzomib and dexamethasone. This new analysis compared patients with early versus late relapse. The second Sarclisa oral presentation highlights updated longer-term efficacy data following subsequent therapy in the pivotal Phase 3 ICARIA-MM trial. It is critical to advance scientific understanding of how individuals who relapse early will respond to subsequent lines of therapy because the earlier a person relapses, the more difficult they can be to treat.
Sanofi is also presenting multiple abstracts from its investigational early pipeline of cutting-edge compounds, such as an open-label, first-in-human, dose-escalation study of Natural Killer Cell Engager (NKCE) SAR443579 as a monotherapy for the treatment of relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high-risk myelodysplasia. Another abstract will highlight the potential of SAR’514, an anti-B cell Maturation Antigen (BCMA) NKCE, for controlling MM tumors in vivo.
Since 2019, Sanofi’s oncology pipeline has doubled, with a dozen next-generation, potential first- or best-in-class compounds entering clinical trials. Much of this growth is a result of an acceleration of in-house research and development capabilities, as well as building external partnerships, particularly in early portfolio, including for MM and other hematologic malignancies.
Source link: https://www.sanofi.com/